Helix BioPharma Corp. (HBP.TO)
CAD 0.78
(0.0%)
CAD 0.78
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 1.48 Million CAD | 44.7% |
| 2023 | 1.02 Million CAD | -72.41% |
| 2022 | 3.73 Million CAD | -8.24% |
| 2021 | 4.06 Million CAD | -17.14% |
| 2020 | 4.9 Million CAD | 421.91% |
| 2019 | 940 Thousand CAD | -18.05% |
| 2018 | 1.14 Million CAD | -47.55% |
| 2017 | 2.18 Million CAD | -51.05% |
| 2016 | 4.46 Million CAD | -42.69% |
| 2015 | 7.79 Million CAD | -0.73% |
| 2014 | 7.85 Million CAD | 33.83% |
| 2013 | 5.86 Million CAD | -22.95% |
| 2012 | 7.61 Million CAD | -68.75% |
| 2011 | 24.37 Million CAD | 34.54% |
| 2010 | 18.11 Million CAD | -6.24% |
| 2009 | 19.31 Million CAD | -10.83% |
| 2008 | 21.66 Million CAD | 51.8% |
| 2007 | 14.27 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 344 Thousand CAD | -81.85% |
| 2024 Q1 | 1.89 Million CAD | 84.16% |
| 2024 Q3 | 1.14 Million CAD | 232.85% |
| 2024 Q4 | 1.48 Million CAD | 30.04% |
| 2023 Q3 | 1.58 Million CAD | -50.39% |
| 2023 Q4 | 1.02 Million CAD | -35.12% |
| 2023 FY | 1.02 Million CAD | -72.41% |
| 2023 Q1 | 4.8 Million CAD | 28.71% |
| 2023 Q2 | 3.19 Million CAD | -33.41% |
| 2022 Q4 | 3.73 Million CAD | 59.74% |
| 2022 FY | 3.73 Million CAD | -8.24% |
| 2022 Q1 | 2.31 Million CAD | -43.1% |
| 2022 Q2 | 944 Thousand CAD | -59.19% |
| 2022 Q3 | 2.33 Million CAD | 147.35% |
| 2021 Q1 | 4.57 Million CAD | -6.69% |
| 2021 FY | 4.06 Million CAD | -17.14% |
| 2021 Q2 | 5 Million CAD | 9.24% |
| 2021 Q3 | 3.02 Million CAD | -39.55% |
| 2021 Q4 | 4.06 Million CAD | 34.47% |
| 2020 Q1 | 2.43 Million CAD | 159.04% |
| 2020 FY | 4.9 Million CAD | 421.91% |
| 2020 Q4 | 4.9 Million CAD | -11.78% |
| 2020 Q2 | 2.73 Million CAD | 12.48% |
| 2020 Q3 | 5.56 Million CAD | 103.03% |
| 2019 FY | 940 Thousand CAD | -18.05% |
| 2019 Q1 | 1.78 Million CAD | 55.19% |
| 2019 Q2 | 1.19 Million CAD | -32.87% |
| 2019 Q3 | 1.59 Million CAD | 33.81% |
| 2019 Q4 | 940 Thousand CAD | -41.21% |
| 2018 Q2 | 2.65 Million CAD | -35.21% |
| 2018 Q1 | 4.09 Million CAD | 87.24% |
| 2018 FY | 1.14 Million CAD | -47.55% |
| 2018 Q4 | 1.14 Million CAD | -33.08% |
| 2018 Q3 | 1.71 Million CAD | -35.39% |
| 2017 Q1 | 3.24 Million CAD | -27.31% |
| 2017 Q2 | 2.49 Million CAD | -23.25% |
| 2017 FY | 2.18 Million CAD | -51.05% |
| 2017 Q4 | 2.18 Million CAD | -3.61% |
| 2017 Q3 | 2.26 Million CAD | -8.99% |
| 2016 Q2 | 3.27 Million CAD | -42.53% |
| 2016 FY | 4.46 Million CAD | -42.69% |
| 2016 Q4 | 4.46 Million CAD | -19.97% |
| 2016 Q3 | 5.58 Million CAD | 70.68% |
| 2016 Q1 | 5.69 Million CAD | -26.99% |
| 2015 Q2 | 3.56 Million CAD | -36.33% |
| 2015 FY | 7.79 Million CAD | -0.73% |
| 2015 Q1 | 5.59 Million CAD | -28.78% |
| 2015 Q4 | 7.79 Million CAD | -22.02% |
| 2015 Q3 | 9.99 Million CAD | 180.74% |
| 2014 Q3 | 3.66 Million CAD | -33.62% |
| 2014 FY | 7.85 Million CAD | 33.83% |
| 2014 Q2 | 5.51 Million CAD | 49.54% |
| 2014 Q1 | 3.69 Million CAD | -37.12% |
| 2014 Q4 | 7.85 Million CAD | 114.39% |
| 2013 Q4 | 5.86 Million CAD | -28.01% |
| 2013 FY | 5.86 Million CAD | -22.95% |
| 2013 Q1 | 5.82 Million CAD | -23.48% |
| 2013 Q2 | 10.26 Million CAD | 76.13% |
| 2013 Q3 | 8.15 Million CAD | -20.59% |
| 2012 Q3 | 10 Million CAD | -37.57% |
| 2012 Q2 | 16.02 Million CAD | -26.2% |
| 2012 FY | 7.61 Million CAD | -68.75% |
| 2012 Q4 | 7.61 Million CAD | -23.86% |
| 2012 Q1 | 21.7 Million CAD | -10.92% |
| 2011 FY | 24.37 Million CAD | 34.54% |
| 2011 Q4 | 24.37 Million CAD | 0.0% |
| 2010 FY | 18.11 Million CAD | -6.24% |
| 2009 FY | 19.31 Million CAD | -10.83% |
| 2008 FY | 21.66 Million CAD | 51.8% |
| 2007 FY | 14.27 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Appili Therapeutics Inc. | 1.49 Million CAD | 0.094% |
| Eupraxia Pharmaceuticals Inc. | 26.72 Million CAD | 94.428% |
| Microbix Biosystems Inc. | 35.65 Million CAD | 95.824% |
| Medicenna Therapeutics Corp. | 19.13 Million CAD | 92.218% |
| Satellos Bioscience Inc. | 44.29 Million CAD | 96.639% |
| Oncolytics Biotech Inc. | 38.82 Million CAD | 96.164% |
| Sernova Corp. | 22.1 Million CAD | 93.265% |